Level of MIP-1α in Marrow Plasma of Patients with Multiple Myeloma

[Objective] To investigate the levels of macrophage inflammatory protein (MIP)-1alpha in the marrow plasma of the patients with multiple myeloma and the clinic significance. [Methods] MIP -1α was quantified using ELISA assay in 43 multiple myeloma, 15 controls, and 37 post therapy of three course. [Results] ⑴About 65.1% patients with multiple myeloma had increased levels of MIP -1α. A significantly larger proportion of multiple myeloma patients had increased levels of MIP-1α compared to the control (t=3.569,P=0 0.01), a significantly larger proportion of multiple myeloma patients with active disease had increased levels of MIP-1α compared to normal controls, other hematological diseases controls and patients with multiple myeloma with inactive disease(P 0.05). A significantly larger proportion of multiple myeloma patients with more than 2 sites bone destruction had increased levels of MIP-1α compared to the less 2 sites bone destruction (t=5.56,P =0).(2)The levels of MIP -1α in responded patients with multiple myeloma after 3 course of treatment was much higher than those in unresponded patients(t =3.237,P=0 0.05).⑶MIP -1α levels significantly correlated with red blood cell, albumin, β2-microglobulin, the presence of bone lesions and Durie-Salmon stages(P 0.05). [Conclusion] ⑴Most of patients with multiple myeloma had increased levels of MIP -1α in marrow plasma. The levels of MIP-1α can indicate bone disease and myeloma burden. The levels of MIP-1α quantified regularly can forecast curative efficiency.